Agenus completes patient enrolment in HSV-2 therapeutic vaccine study
Biotechnology company Agenus has finished enrolling patients in a double-blind, multicentre, randomised Phase II study of its recombinant therapeutic vaccine for the treatment of genital herpes in herpes simplex virus-2 (HSV-2) positive patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cold Sores | Genital Herpes | Herpes | Pharmaceuticals | Study | Vaccines